Beverage Companies Look to Capitalize on CBD's Benefits and Accessibility
While other segments are projected to grow, they are nonetheless expected to lag behind the exponential growth of the CBD product segment.
- While other segments are projected to grow, they are nonetheless expected to lag behind the exponential growth of the CBD product segment.
- In particular, the U.S. Food and Drug Administration has already legalized a CBD-based drug, Epidiolex, which is used to treat epilepsy.
- CBD is a non-psychoactive compound that has been broadly demonstrated to offer powerful health benefits, addressing a variety of challenging medical conditions.
- This groundbreaking technology will enable companies producing nano-scale CBD emulsion products to meet the ever-increasing demand for CBD nanoemulsion products.